Mohammed Razeeth Shait Mohammed
Overview
Explore the profile of Mohammed Razeeth Shait Mohammed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfaleh M, Razeeth Shait Mohammed M, Hashem A, Abujamel T, Alhakamy N, Imran Khan M
Saudi J Biol Sci
. 2023 Dec;
31(1):103871.
PMID: 38107766
Epithelial cancer cells rely on the extracellular matrix (ECM) attachment in order to spread to other organs. Detachment from the ECM is necessary for these cells to seed in other...
2.
Dalhat M, Razeeth Shait Mohammed M, Alkhatabi H, Rehan M, Ahmad A, Choudhry H, et al.
Clin Transl Med
. 2022 Sep;
12(9):e1045.
PMID: 36149760
Background: N-4 cytidine acetylation (ac4C) is an epitranscriptomics modification catalyzed by N-acetyltransferase 10 (NAT10); important for cellular mRNA stability, rRNA biogenesis, cell proliferation and epithelial to mesenchymal transition (EMT). However,...
3.
Razeeth Shait Mohammed M, Alzahrani F, Hosawi S, Choudhry H, Imran Khan M
Int J Mol Sci
. 2022 Jun;
23(12).
PMID: 35743098
Leukemia is one of the most common primary malignancies of the hematologic system in both children and adults and remains a largely incurable or relapsing disease. The elucidation of disease...
4.
Alkhatabi H, Zohny S, Razeeth Shait Mohammed M, Choudhry H, Rehan M, Ahmad A, et al.
Antioxidants (Basel)
. 2022 Mar;
11(3).
PMID: 35326111
Venetoclax (ABT199) is a selective B-cell lymphoma 2 (BCL-2) inhibitor. The US FDA recently approved it to be used in combination with low-dose cytarabine or hypomethylating agents in acute myeloid...
5.
Nur S, Razeeth Shait Mohammed M, Zamzami M, Choudhry H, Ahmad A, Ateeq B, et al.
Metabolites
. 2022 Mar;
12(3).
PMID: 35323710
Tumor cells detached from the extracellular matrix (ECM) undergo anoikis resistance and metabolic reprogramming to facilitate cancer cell survival and promote metastasis. During ECM detachment, cancer cells utilize genomic methylation...
6.
Razeeth Shait Mohammed M, Zamzami M, Choudhry H, Ahmed F, Ateeq B, Imran Khan M
Front Cell Dev Biol
. 2022 Feb;
10:780176.
PMID: 35186918
Epithelial cancer cells that lose attachment from the extracellular matrix (ECM) to seed in a distant organ often undergo anoikis's specialized form of apoptosis. Recently, KDM3A (H3K9 demethylase) has been...
7.
Alzahrani F, Razeeth Shait Mohammed M, Alkarim S, Azhar E, El-Magd M, Hawsawi Y, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638812
Extracellular vesicles (EVs) carry important biomolecules, including metabolites, and contribute to the spread and pathogenesis of some viruses. However, to date, limited data are available on EV metabolite content that...
8.
Dalhat M, Razeeth Shait Mohammed M, Ahmad A, Imran Khan M, Choudhry H
J Cell Biochem
. 2021 Oct;
122(12):1936-1945.
PMID: 34605570
Remodelin is a small molecule inhibitor of N-acetyltransferase 10 (NAT10), reported to reverse the effect of cancer conditions such as epithelial to mesenchymal transition, hypoxia, and drug resistance. We analysed...
9.
Alzahrani A, Razeeth Shait Mohammed M, Alghamdi R, Ahmad A, Zamzami M, Choudhry H, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34067305
Leukemia is persistently a significant cause of illness and mortality worldwide. Urolithins, metabolites of ellagic acid and ellagitannins produced by gut microbiota, showed better bioactive compounds liable for the health...
10.
Tabrez S, Razeeth Shait Mohammed M, Jabir N, Imran Khan M
Biol Chem
. 2021 May;
402(6):749-757.
PMID: 33951765
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality around the world. Early diagnosis of CVD could provide the opportunity for sensible management and better clinical outcome along...